CA
NZ
UK
AU
IND
US
Emergent Health Corp (OTC:EMGE) is the kind of ticker that surfaces on lists of the market's lowest-priced shares, trading at a fraction of a cent with no movement in the last closing session. The harder truth is that the company has left almost no …
● The recent daily decline in CTXR shares has no single identifiable public catalyst and is characteristic of a low-priced, thinly capitalized stock.
A pullback of nearly 7% in a single session has drawn eyes to Cuprina Holdings (Cayman) Limited (NASDAQ: CUPR), a newly public, Singapore-based biomedical micro-cap trading around $2.91. For a company this small, sharp swings are routine, and the recent decline does not trace …
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a clinical-stage company chasing a niche but meaningful anticoagulation market, and its shares drifted modestly lower in early September 2026. Fresh off a second-quarter update and an FDA-endorsed path into late-stage development, the micro-cap has been reshaping its story …
A medical-device company built around a single flagship therapy is only as strong as its commercial execution, and 2026 has tested that reality for CVRx. Shares of CVRx, Inc (NASDAQ: CVRX) have slipped toward the low end of their 52-week range after a second …
● Consistent with the auto-generated framing, there is no single verified catalyst behind the "steady" characterization.
Dare Bioscience, Inc. (NASDAQ:DARE) has quietly turned into one of the more active names in women's health this summer, even as its shares trade below a dollar. The Nasdaq-listed company, ticker DARE, spent August 2026 stacking up developments: a fresh federal research grant, new …
A quiet uptick in Citius Oncology, Inc (NASDAQ:CTOR) shares belies a more interesting story unfolding beneath the surface: the commercial ramp of an FDA-approved lymphoma therapy. The small-cap oncology company, majority owned by Citius Pharmaceuticals, is roughly a year into launching its lead product …
A blood-purification pioneer with a commercial product in Europe and a long-sought U.S. approval still in reach, CytoSorbents Corporation (NASDAQ: CTSO) has become a study in how hard the last mile of regulatory access can be. Another single-session slide has drawn fresh attention to …
● The small daily decline in CMPX shares has no single identifiable public catalyst and is consistent with routineVolatilityin a pre-commercial biotech.
Please wait processing your request...